Autism Spectrum Disorder Clinical Trial
Official title:
A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
Verified date | January 2017 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314 in adult participants with ASD. In Stage I of the study, participants will be randomized in 2:1 to receive daily oral doses of 1.5 milligrams (mg) RG7314 or placebo for 12 weeks. After an independent safety review, the study may proceed to Stage II. In Stage II of the study, additional participants will be randomized in 2:1 to receive daily oral doses of 4 mg RG7314 or placebo for 12 weeks. After an independent safety review, Stage III will be started wherein additional participants will be randomized in 2:1 to receive daily oral doses of 10 mg RG7314 or placebo for 12 weeks. During Stage III, safety will be reviewed by independent safety review twice and if no safety signal is observed, then additional participants will be randomized in 1:1:1 either to receive 1.5 milligrams per day (mg/day) or 10 mg/day RG7314 orally or placebo for 12 weeks in Stage IV.
Status | Completed |
Enrollment | 223 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Participants meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for ASD and Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10) criteria for Autism diagnosis - SRS-2 (T-score) greater than or equal to (>/=) 66 - CGI-S >/=4 (moderately ill) - Participants have an Intelligence Quotient (IQ) >/=70 (Wechsler Abbreviated State of Intelligence) - A body mass index (BMI) between 18 to 40 kilograms per square meter (kg/m^2) inclusive - Language, hearing and vision compatible with the study measurements as judged by the investigator - Lives with (or has substantial periods of contact with) a caregiver who is willing and able to attend visits when required, oversee the participant's compliance with protocol-specified procedures and study medication dosing, and report on the participant's status via completion of study assessments. Any period of absence must be covered by another caregiver. Non-cohabitating caregiver(s) must spend sufficient time with the participant so that, in the opinion of the investigator, the caregiver(s) can reliably assess participant's mental status, activities and behavior. Exclusion Criteria: - Alcohol and/or substance abuse/dependence during the last 12 months - A significant risk for suicidal behavior, in the opinion of the investigator - Systolic blood pressure greater than (>) 140 or less than (<) 90 millimeters of mercury (mm Hg), and diastolic blood pressure >90 or less than (<) 50 mm Hg - Resting pulse rate >90 or <40 beats per minute - Use of prohibited medications or herbal remedies within 2 weeks prior to randomization, or 5 half-lives (whichever is longer) - Initiation of a new major change in psychological intervention within 4 weeks prior to randomization. Minor changes in ongoing treatment are not considered significant - Participation in an investigational drug or device study within 60 days prior to randomization |
Country | Name | City | State |
---|---|---|---|
United States | The Kennedy Krieger Institute | Baltimore | Maryland |
United States | Northwest Clinical Research Center | Bellevue | Washington |
United States | Pacific Institute of Medical Sciences | Bothell | Washington |
United States | Montefiore Medical Center; Departments of Psychiatry & Biobehavioral Science | Bronx | New York |
United States | DBA IMMUNOe Int'l Res Center | Centennial | Colorado |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | University Hospitals | Cleveland | Ohio |
United States | Emory University School of Medicine; Department of Human Genetics & Pediatrics | Decatur | Georgia |
United States | Neurology offices of south florida | Delray Beach | Florida |
United States | DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development | Durham | North Carolina |
United States | Massachusetts General Hospital | Lexington | Massachusetts |
United States | University of Minnesota; Clin. Neuro Research Unit | Minneapolis | Minnesota |
United States | Vanderbilt Medical Center | Nashville | Tennessee |
United States | Yale University; Yale Child Study Center | New Haven | Connecticut |
United States | Mount Sinai School of Medicine; Seaver Autism Center | New York | New York |
United States | Research Centers of America, LLC | Oakland Park | Florida |
United States | Nathan S. Kline Institute for Psychiatric Research | Orangeburg | New York |
United States | Compass Research | Orlando | Florida |
United States | Southwest Autism Research & Resource Center | Phoenix | Arizona |
United States | UPMC Western Psychiatric Institute and Clinic | Pittsburgh | Pennsylvania |
United States | Neuroscientific Insights | Rockville | Maryland |
United States | University of California Davis | Sacramento | California |
United States | Road Runner Research | San Antonio | Texas |
United States | PCSD Feighner Research | San Diego | California |
United States | University of California at San Francisco | San Francisco | California |
United States | Seattle Children's Research Institute | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Social Communication Deficits as Measured by Social Responsiveness Scale 2 (SRS-2) | Baseline, Week 12 | ||
Primary | Percentage of Participants with Suicidality, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline up to Week 12 | ||
Primary | Percentage of Participants With Adverse Events | From Baseline up to Week 18 | ||
Secondary | Change From Baseline in Behavior/Symptoms as Measured by Aberrant Behavior Checklist (ABC) | Baseline, Week 12 | ||
Secondary | Change From Baseline in Behavior/Symptoms as Measured by Repetitive Behavior Scale-Revised (RBS-R) | Baseline, Week 12 | ||
Secondary | Change From Baseline in Behavior/Symptoms as Measured by Anxiety, Depression and Mood Scale (ADAMS) | Baseline, Week 12 | ||
Secondary | Measure: Change From Baseline in Behavior/Symptoms as Measured by State-Trait Anxiety Inventory (STAI) | Baseline, Week 12 | ||
Secondary | Change From Baseline in Clinical Global Impressions as Measured by Clinical Global Impressions Improvement (CGI-I) Scale | Baseline, Week 12 | ||
Secondary | Change From Baseline in Adaptive Functioning and Skills as Measured by Vineland-II Adaptive Behavior Scale (VABS) | Baseline, Week 12 | ||
Secondary | Plasma Concentration of RG7314 | Pre-dose (0 hours [hr]), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | Plasma Concentration of RG7314 Metabolite M3 | Pre-dose (0 hr), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Concentration (AUClast) of RG7314 | Pre-dose (0 hr), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | AUClast of RG7314 Metabolite M3 | Pre-dose (0 hr), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | Maximum Observed Plasma Concentration (Cmax) of RG7314 | Pre-dose (0 hr), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | Cmax of RG7314 Metabolite M3 | Pre-dose (0 hr), and 2, 4, 6 hrs post-dose on Day 1, 14, 84; pre-dose (0 hr) on Day 42; any time during early withdrawal visit (up to Week 12) | ||
Secondary | Percentage of Participants With Clinical Response, Defined as At Least 25% Improvement in the SRS-2 Score With a CGI-I Score of 1 or 2 | From Baseline to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05207956 -
App for Strengthening Services In Specialized Therapeutic Support
|
N/A | |
Completed |
NCT03286621 -
Development of Eye-tracking Based Markers for Autism in Young Children
|
||
Completed |
NCT02608333 -
Efficiency of Early Intervention for Autism Spectrum Disorder
|
N/A | |
Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
Active, not recruiting |
NCT06259539 -
A YouTube Curriculum for Children With Autism and Obesity
|
N/A | |
Active, not recruiting |
NCT06303791 -
Digital-based Psychosocial Intervention for Parents of Children With Neurodevelopmental Disorders
|
N/A | |
Enrolling by invitation |
NCT05017779 -
A Hybrid Effectiveness-implementation Trial of a High School-based Executive Function Treatment for Autistic Youth
|
N/A | |
Completed |
NCT04772898 -
Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder
|
N/A | |
Recruiting |
NCT04987541 -
The Therapeutic Effect of TBS Stimulation on Emotion Regulation in Autism Spectrum Disorder
|
N/A | |
Completed |
NCT04308915 -
Mobile-based Games for Cognitive Training in Children With Neurodevelopmental Disorders
|
N/A | |
Completed |
NCT06038435 -
The Effect of Cognitive Orientation Approach on Daily Occupational Performance With Autism Spectrum Disorder
|
N/A | |
Terminated |
NCT04049981 -
Investigation of Mechanisms of Action in Superpower Glass
|
Phase 1/Phase 2 | |
Completed |
NCT03693313 -
The Effect of CrossFit Kids on Social Skills in Children With Autism Spectrum Disorder (CrossFit KAMP)
|
N/A | |
Recruiting |
NCT04107064 -
Achieving Steady Work Among Adults With Autism Through Specialized Employment Program
|
N/A | |
Recruiting |
NCT03812068 -
Parent-mediated Developmental Behavioral Intervention
|
N/A | |
Completed |
NCT03206996 -
Exposure Therapy for Auditory Sensitivity in Autism
|
N/A | |
Completed |
NCT02299700 -
Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder
|
N/A | |
Completed |
NCT03422016 -
Electroretinogram in Autistic Spectrum Disorders
|
||
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Recruiting |
NCT05114538 -
Improving the Part C Early Intervention Service Delivery System for Children With ASD
|
N/A |